Edition:
United Kingdom

Ascendis Pharma A/S (ASND.OQ)

ASND.OQ on NASDAQ Stock Exchange Global Select Market

66.29USD
18 May 2018
Change (% chg)

$-0.63 (-0.94%)
Prev Close
$66.92
Open
$66.81
Day's High
$67.14
Day's Low
$66.01
Volume
18,121
Avg. Vol
41,315
52-wk High
$69.50
52-wk Low
$21.95

Latest Key Developments (Source: Significant Developments)

Ascendis Pharma Announces Dosing Of First Subjects In Phase 1 Trial Of Transcon CNP
Tuesday, 8 May 2018 

May 8 (Reuters) - Ascendis Pharma A/S ::ASCENDIS PHARMA A/S ANNOUNCES DOSING OF FIRST SUBJECTS IN PHASE 1 TRIAL OF TRANSCON CNP.ASCENDIS PHARMA A/S - ANTICIPATES TOP-LINE DATA FROM PHASE 1 TRIAL TO BE AVAILABLE IN Q4 OF 2018.  Full Article

Ascendis Pharma Reports Full Year 2017 Financial Results
Wednesday, 28 Mar 2018 

March 28 (Reuters) - Ascendis Pharma A/S ::ASCENDIS PHARMA A/S REPORTS FULL YEAR 2017 FINANCIAL RESULTS.ASCENDIS PHARMA A/S - RARE DISEASE ENDOCRINOLOGY PIPELINE ADVANCES, WITH SIGNIFICANT MILESTONES ANTICIPATED OVER NEXT TWELVE MONTHS.ASCENDIS PHARMA A/S - AS OF DEC 31, 2017, HAD CASH AND CASH EQUIVALENTS OF EUR 195.4 MILLION COMPARED TO EUR 180.3 MILLION AS OF DEC 31, 2016.  Full Article

Ascendis Pharma A/S Announces Proposed Public Offering Of ADSS
Tuesday, 20 Feb 2018 

Feb 20 (Reuters) - Ascendis Pharma A/S ::ASCENDIS PHARMA A/S ANNOUNCES PROPOSED PUBLIC OFFERING OF ADSS.ASCENDIS PHARMA A/S - COMMENCED OFFERING OF $150 MILLION ADSS.  Full Article

Ascendis Pharma Initiates Submissions In Australia To Enter Study With Transcon CNP
Wednesday, 20 Dec 2017 

Dec 20 (Reuters) - Ascendis Pharma A/S ::ASCENDIS PHARMA SAYS ON DEC 20, INITIATED REGULATORY SUBMISSIONS IN AUSTRALIA TO ENTER INTO FIRST HUMAN CLINICAL STUDY WITH TRANSCON CNP - SEC FILING.  Full Article

Ascendis Pharma A/S Q3 loss per share EUR 1.04
Thursday, 16 Nov 2017 

Nov 16 (Reuters) - Ascendis Pharma A/S ::Ascendis Pharma A/S reports third quarter 2017 financial results.Q3 loss per share EUR 1.04.Q3 earnings per share view EUR -0.74 -- Thomson Reuters I/B/E/S.  Full Article

Ascendis Pharma A/S reports dosing of subjects in phase 1 trial of transcon pth
Tuesday, 26 Sep 2017 

Sept 26 (Reuters) - Ascendis Pharma A/S ::Ascendis Pharma A/S announces dosing of subjects in phase 1 trial of Transcon pth.Ascendis Pharma A/S says ‍phase 1 trial evaluates single ascending doses and ten multiple daily doses of transcon pth​.  Full Article

Ascendis Pharma Q2 loss per share EUR 0.94
Friday, 18 Aug 2017 

Aug 18 (Reuters) - Ascendis Pharma A/S :Ascendis Pharma A/S reports second quarter 2017 financial results.Q2 loss per share EUR 0.94.Q2 earnings per share view EUR -0.73 -- Thomson Reuters I/B/E/S.Ascendis Pharma A/S - qtrly revenue EUR 444,000 versus EUR 1.1 million.  Full Article

Ascendis Pharma says initiated regulatory submissions in Australia for entry into human clinical study with transcon parathyroid hormone
Monday, 26 Jun 2017 

June 26 (Reuters) - Ascendis Pharma A/S :Ascendis Pharma - initiated regulatory submissions in australia to enable co's entry into its first human clinical study with transcon parathyroid hormone.  Full Article

Ascendis Pharma A/S Q1 loss per share eur 0.78
Tuesday, 23 May 2017 

May 23 (Reuters) - Ascendis Pharma A/S :Ascendis pharma a/s reports first quarter 2017 financial results.Q1 loss per share eur 0.78.Ascendis pharma a/s qtrly revenue eur 372,000 versus eur 1.26 million.Ascendis pharma a/s - as of march 31, 2017, company had cash and cash equivalents of eur 157.6 million compared to eur 180.3 million as of december 31, 2016.  Full Article

Ascendis Pharma files to say may offer, sell up to $400 million ordinary shares from time to time in one or more offerings
Wednesday, 22 Mar 2017 

Ascendis Pharma A/S :Ascendis Pharma A/S - files to say may offer, sell up to $400 million in aggregate of our ordinary shares (or adss representing such shares) from time to time in one or more offerings.  Full Article

BRIEF-Ascendis Pharma Announces Dosing Of First Subjects In Phase 1 Trial Of Transcon CNP

* ASCENDIS PHARMA A/S ANNOUNCES DOSING OF FIRST SUBJECTS IN PHASE 1 TRIAL OF TRANSCON CNP